about
Analysis of heritability and shared heritability based on genome-wide association studies for thirteen cancer typesNot all epidermal growth factor receptor mutations in lung cancer are created equal: Perspectives for individualized treatment strategyMET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling.EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors.MET gene exon 14 deletion created using the CRISPR/Cas9 system enhances cellular growth and sensitivity to a MET inhibitor.Lineage-specific dependency of lung adenocarcinomas on the lung development regulator TTF-1Surgical implications of the new IASLC/ATS/ERS adenocarcinoma classificationInternational association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinomaMeta-analysis of genome-wide association studies identifies multiple lung cancer susceptibility loci in never-smoking Asian womenGenome-wide association analysis identifies new lung cancer susceptibility loci in never-smoking women in AsiaA 25-signal proteomic signature and outcome for patients with resected non-small-cell lung cancer.Efficacy and safety of weekly nab-paclitaxel plus carboplatin in patients with advanced non-small cell lung cancer.Combined carboplatin and cisplatin therapy in patients with advanced non-small cell lung cancer.CRIPTO1 expression in EGFR-mutant NSCLC elicits intrinsic EGFR-inhibitor resistance.Reduced expression of class II histone deacetylase genes is associated with poor prognosis in lung cancer patients.Prognostic implication of predominant histologic subtypes of lymph node metastases in surgically resected lung adenocarcinomaEGFR Exon 18 Mutations in Lung Cancer: Molecular Predictors of Augmented Sensitivity to Afatinib or Neratinib as Compared with First- or Third-Generation TKIs.Impact of EGFR mutation analysis in non-small cell lung cancer.Epidermal growth factor receptor mutations in small cell lung cancer.Molecular epidemiology of lung cancer and geographic variations with special reference to EGFR mutations.Management of ground-glass opacities: should all pulmonary lesions with ground-glass opacity be surgically resected?Collateral chemoresistance to anti-microtubule agents in a lung cancer cell line with acquired resistance to erlotinib.A rapid, sensitive assay to detect EGFR mutation in small biopsy specimens from lung cancer.EGFR mutations in patients with brain metastases from lung cancer: association with the efficacy of gefitinib.Prognostic implication of transforming growth factor alpha in adenocarcinoma of the lung--an immunohistochemical study.Clinical, Pathological, and Molecular Features of Lung Adenocarcinomas with AXL Expression.Progression after spontaneous regression in lung large cell neuroendocrine carcinoma: Report of a curative resection.Increased prevalence of EGFR-mutant lung cancer in women and in East Asian populations: analysis of estrogen-related polymorphismsSmall cell lung cancer transformation and T790M mutation: complimentary roles in acquired resistance to kinase inhibitors in lung cancer.Prognosis and segment-specific nodal spread of primary lung cancer in the right lower lobe.Biological and clinical implications of EGFR mutations in lung cancer.Dietary factors and lung cancer risk in Japanese: with special reference to fish consumption and adenocarcinomas.Integrated clinical and basic studies related to circumventing non-small cell lung cancer drug resistance.Oncogene swap as a novel mechanism of acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitor in lung cancerEpidermal growth factor receptor mutations in lung cancers.Mutations in the epidermal growth factor receptor gene and effects of EGFR-tyrosine kinase inhibitors on lung cancers.A phase II trial evaluating the efficacy and safety of perioperative pirfenidone for prevention of acute exacerbation of idiopathic pulmonary fibrosis in lung cancer patients undergoing pulmonary resection: West Japan Oncology Group 6711 L (PEOPLE SEGFR T790M mutation: a double role in lung cancer cell survival?Epidermal growth factor receptor in relation to tumor development: EGFR gene and cancer.Advances in target therapy for lung cancer.
P50
Q24170413-BA897BF5-3782-4E98-9DB3-DDF79E316902Q26744284-3387EEA9-2D30-4F66-9616-AB3B45B882A8Q27851406-E088519C-A451-41FB-AB3B-F54B5325C108Q27851590-8AAAB32E-CB46-4F0E-A2B5-E1749C103DDDQ27853240-2EE32840-8931-45A7-9C78-A0CE31E13DB6Q28235617-0EED5445-0BF6-4B42-848F-0381F6C309A8Q28245205-80ED27F8-C786-460E-BCE2-6EB236F42360Q28303718-C20C940E-5395-43CC-A090-BEA9554DD9EDQ28385292-D17472A1-0249-405D-A6BE-5552BE1896A7Q28943345-B329D448-A594-4CBF-8BC9-93B57A1AF9EAQ33286794-0BBF2E68-4334-42E9-BDB4-3E0CFBB3DAA4Q33406737-941C88D8-7FAA-49C3-861E-145FED4809ABQ33498359-501E621A-30A8-46F7-9A69-8746A7D42489Q33808203-66EABD3D-A76F-41F5-BA71-D01A1D20E27BQ34340318-07EF3134-09CB-4A15-BF83-BB0566805074Q34406294-1DD44985-06AC-4D84-A6E7-58ACE98181CDQ34486675-C166F61C-CE69-4792-9B0F-0415BDF6B997Q34596515-E3444F8C-B718-48F5-9572-87BD19A05482Q34842246-26D5A987-E7A5-49A9-869F-38E0471758C5Q35200585-51751313-D949-475D-94C4-7F73653B0CE0Q35200651-090F1AC5-2DF2-4905-93AD-BD627C94A029Q35602423-7FEE1697-F934-4930-8A0E-E8518F3CC764Q35790221-4728C0E0-7373-46F3-BB61-EBB889328402Q35800614-21D64A94-AA96-454B-AC40-3200E96242FCQ35982524-9408745A-14BD-478A-8C2C-81545F55ECFBQ35995940-348C93AA-D5DB-4C26-99CC-F72455752074Q36051745-855E13BB-E433-4F04-8B37-BD5FB3D940E3Q36082004-4F77C0DE-B4C3-42D1-BC29-66138DCEC583Q36099734-C2B25205-5686-4F72-8EE5-4A4D875EC0D1Q36247846-E7EB574C-CF66-49D1-A286-FF47EEDD83E6Q36540571-D7DD2203-61D7-426F-8B31-CCCCE1281F48Q36622980-8F122A34-6702-429E-A279-61D2455B1C20Q36740366-446383C3-1508-45A0-8DC5-ECB1E8630698Q36801144-ED7F2C22-CBF2-4BDF-A3F6-A6B4A9DD11E7Q36817294-3209849F-6D6C-4AAB-A3F7-9BC03FE6B9A2Q37110011-97D4368C-4855-4AD2-AE1C-20C0346FAF73Q37118198-12020B28-F181-49BE-BBEC-8FB1E82C0333Q37354807-9566D051-1C56-4125-8D7A-D58D8AEEAAC4Q37634598-E48B341B-1380-4236-B233-5A71A99E069CQ37661928-2236815C-BFA8-49BA-A7D2-9118C6AC87F2
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Tetsuya Mitsudomi
@ast
Tetsuya Mitsudomi
@en
Tetsuya Mitsudomi
@es
Tetsuya Mitsudomi
@nl
Tetsuya Mitsudomi
@sl
type
label
Tetsuya Mitsudomi
@ast
Tetsuya Mitsudomi
@en
Tetsuya Mitsudomi
@es
Tetsuya Mitsudomi
@nl
Tetsuya Mitsudomi
@sl
prefLabel
Tetsuya Mitsudomi
@ast
Tetsuya Mitsudomi
@en
Tetsuya Mitsudomi
@es
Tetsuya Mitsudomi
@nl
Tetsuya Mitsudomi
@sl
P106
P1153
7006672879
P21
P31
P496
0000-0001-9860-8505
P569
2000-01-01T00:00:00Z